Summary of Evidence Related to COVID-19 Vaccine Effectiveness and Breakthrough Infections

There are currently three COVID-19 vaccines authorized under an Emergency Use Authorization in the US and across the US, everyone 16 years or older is currently eligible for vaccination with at least one of the vaccines, with expansion of eligibility down to age 12 likely soon. The vaccine coverage among eligible individuals remains uneven, but high coverage among adults has been achieved in some settings.

Double Dose of Debate: Opinions Vary on Timing of COVID Vaccine Shots as Potential 4th Wave Looms (includes Ruanne Barnabas)

by Lisa Stiffler  / March 19, 2021

With COVID-19 vaccines still in limited supply and case counts threatening to resurge, there is a debate over the benefits of giving more people their first shot and waiting a longer time to administer the second dose, or whether to stay the course and prioritize getting both doses of the Pfizer and Moderna vaccine into arms as quickly as possible.

United World Antiviral Research Network (UWARN) Partners Collaborate to Expand Understanding of New COVID Variants, Key to Future Vaccine Development

The recent recognition of new COVID-19 variants, first detected in South Africa (B.1.135, 501Y.V2), Brazil (P1) and the UK (B.1.1.7) – and the variants’ potential to disrupt vaccine effectiveness and protection from prior COVID-19 infection – is an urgent concern that UWARN partners around the globe are collaborating on to understand.

Opinion: Specialists Back Single-Dose Vaccine Strategy for COVID-19 (includes Ruanne Barnabas)

Even partial protection of one dose could be enough to slow the spread of the virus, the UW Medicine researchers argue in a paper.

MEDIA CONTACT: Susan Gregg - 206.616.6730, sghanson@uw.edu

Giving one dose of the COVID-19 vaccines currently approved in the United States could curtail the spread of the SARS-CoV-19 in the community more quickly than the recommended two doses, say two vaccine experts at the University of Washington School of Medicine.

UW Medicine starts Novavax COVID-19 vaccine clinical trial (includes Scott McClelland)

Volunteer enrollment begins for Phase III clinical trial that will determine the efficacy of Novavax vaccine candidate.

UW Medicine investigators are starting volunteer enrollment for an investigational COVID-19 vaccine clinical trial. The Phase III study will examine whether the Novavax vaccine candidate can protect against SARS-CoV-2, the coronavirus responsible for COVID-19.

How Safe and Effective Are the New Coronavirus Vaccines?

The U.S. Food and Drug Administration (FDA) has granted emergency use for two new coronavirus vaccines, one developed by the drug company Pfizer and the biotech company BioNTech and the other by the biotech company ModernaTX. Both are mRNA vaccines and have similar structure.

Both vaccines contain modified mRNA that provides the instructions for the synthesis of the SARS-CoV-2 spike glycoprotein antigen. Its mRNA is enveloped in lipid nanoparticles (LNPs) to prevent degradation and enhance uptake into cells.

Who Gets COVID-19 Vaccine Next? Older Adults and 'Frontline Essential Workers,' CDC Advisers Recommend (quotes Beth Bell)

By Jacqueline Howard and Jen Christensen, CNN

(CNN)Vaccine advisers to the US Centers for Disease Control and Prevention voted 13-1 on Sunday to recommend that both older adults, ages 75 and older, and "frontline essential workers" including first responders be next in line to receive Covid-19 vaccines.

That would put those people in "Phase 1b" of allocating the vaccine nationwide.

Pages